[Neuroleptic malignant syndrome].
This is a review article on neuroleptic malignant syndrome. Clinical manifestations and differential diagnosis are discussed. Treatment is based on suppression of the drug and administration of bromocriptine and dantrolene. After recovery, neuroleptics should be withheld or a drug with low dopaminergic blocking effect would be selected.
Servicio B, Instituto Psiquiátrico, Santiago de Chile.
P
P
Retamal
D014150:Antipsychotic Agents / Q000009:adverse effects; D001971:Bromocriptine / Q000627:therapeutic use; D003620:Dantrolene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000188:drug therapy
D014150:Antipsychotic Agents; D001971:Bromocriptine; D003620:Dantrolene
Síndrome maligno por neurolépticos.